Stock Detail
PAIN THERAPEUTICS
Sector: Drug Manufacturers Other
Latest Quote @ Fri May 5 21:37:24 (15 min delayed)
| N/A |
N/A |
$2.82 |
-0.04 |
-1.40% |
|
Last Day's Data
| $2.86 |
$2.88 |
$0.00 |
0.00% |
0.00 |
$2.88 |
| $2.85 |
$2.80 |
428,566.00 |
129.65M |
136,268.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 2.93 |
2.90 |
2.85 |
2.82 |
2.77 |
Stock Profile
Pain Therapeutics, Inc., a development stage company, engages in the development of drugs for use in pain management, principally in the area of opioid painkillers. The company's clinical pipeline comprises three proprietary drug candidates, which include Oxytrex, an oral opioid painkiller that is in two Phase III clinical trials for the treatment of severe chronic pain; PTI-901, which is in two Phase III clinical trials to treat men and women with irritable bowel syndrome; and Remoxy, an anti-abuse version of long-acting oxycodone that is in one Phase III clinical trial. It has research and collaboration agreement with Durect Corporation. Pain Therapeutics has a strategic alliance with King Pharmaceuticals, Inc. to develop and commercialize Remoxy and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in South San Francisco, California.
